Zambia's Diabetes Clinics Screen for Retinopathy While Insulin Runs Short

Zambia's diabetes clinics have learned to look at the eye. Retina cameras now sit in primary care rooms in Lusaka and a handful of provincial towns, and nurses use them to catch diabetic retinopathy before it steals sight. The screening works. The trouble is what patients say while they wait for the image: the insulin ran out at the clinic again, and they have been stretching doses for weeks.

The Eye Clinic Queue in Lusaka

At a busy primary clinic in Lusaka, the retina camera is a compact unit on a wheeled stand, operated by a nurse who has learned to dilate pupils and capture images in near-darkness. Patients arrive early and wait through the morning. Many have walked or paid for minibus fares they can barely spare. The queue moves slowly because each image needs a clear view and a steady patient.

The same waiting room tells a second story. When the pharmacist's window opens, a crowd forms and often disperses with partial answers. Insulin is not always on the shelf. Patients trade information about which clinic had stock last week, which pharmacy sells vials at a price they can reach, and how far they are willing to travel.

Retinopathy screening has become the reliable part of the visit. Insulin supply has not. A patient can leave with a clear picture of their retina and no clear plan for the next month's doses. That mismatch is the central problem these clinics now face.

Retinopathy Screening as Triage

Nurses trained for retinal imaging have turned the eye check into a form of triage. A normal image means reassurance and a repeat in a year. Bleeding, microaneurysms, or new vessels mean an urgent referral to an ophthalmologist, sometimes in another city. The referral pathway was built for blindness prevention, and it works when patients can reach the specialist.

The same nurses are now watching a different kind of damage. When insulin is short, blood glucose climbs, and retinopathy progresses faster. A patient who screened clean last year can return with early changes this year. The camera records the consequence of a supply failure that happened months earlier, far from the eye room.

Rationing is common. Patients describe splitting doses, skipping evening injections, or switching to whatever tablets they can afford. Some choose food over medicine for their children and take the risk themselves. The clinic sees the result in the retina long before it sees it in a stock ledger.

What Patients Actually Experience

Blurred vision is often the first prompt to seek care. A trader in her fifties notices she cannot read prices on a phone screen. A driver finds headlights smear at night. By the time they reach a clinic, many have had high blood glucose for years without a diagnosis, and the retina already shows the wear.

Monthly insulin costs strain households. Even when a vial is available, the syringe, the test strips, and the travel add up. Some patients borrow from relatives or sell produce early. Others reduce meals to make the insulin last, which creates its own swings and risks.

The screening then finds what treatment cannot always fix. Laser treatment and injections can slow retinopathy, but they do not undo years of high glucose, and they cannot substitute for the insulin that never arrived. Clinicians describe the frustration of catching damage early with no reliable way to prevent its cause.

This site has documented a similar pattern in Nigeria, where diabetes diagnoses arrive after kidney damage starts. The Zambian eye clinics are seeing the same late arrival, one organ system over.

The Supply Chain Gap

Central procurement delays are a recurring theme. Orders placed through national channels can take months to reach districts, and the timing rarely matches demand. When a shipment lands, clinics may receive less than requested, and the shortfall is absorbed by patients who pay retail prices.

Rural clinics report longer stockouts than urban ones. Distance, road conditions, and limited cold chain capacity all shorten the shelf life of insulin that does arrive. A refrigerator that fails for a day can spoil a month's supply, and replacement is not quick.

Donor funding has largely supported screening and training, which are visible and measurable. Insulin is a recurring cost with no end date, and it competes with every other line in a health budget. The result is a program that detects a complication better than it prevents one.

A related piece on this site describes how Zambia trains more midwives while delivery wards stay understaffed. The pattern is familiar: build the workforce and the screening, then discover the consumables are the bottleneck.

Documented Evidence and Limits

The World Health Organization has noted rising diabetes prevalence across African countries, with urbanisation and changing diets driving much of the increase. Screening programs in several countries have shown that retinal imaging at primary level can detect more cases earlier than referral-only systems.

Insulin access remains uneven. Surveys of availability in low- and middle-income settings have repeatedly found gaps at public facilities, with patients turning to private pharmacies at higher prices. The figures vary by country and by month, and precise national numbers are hard to pin down.

Few studies track screening and insulin supply together in the same population. That gap matters. A detection rate without a treatment rate tells only half the story, and the half it leaves out is the one patients live with.

The Economics of Insulin Access

Insulin is not a one-time purchase. A patient on daily injections needs a continuous supply, and the cost multiplies when vials are bought in small quantities at retail prices. In many low- and middle-income countries, a month's supply can consume a substantial share of a household's income, though the exact proportion varies widely. When public clinics run out, patients turn to private pharmacies where prices are higher and quality cannot always be assured.

Transport adds another layer. For rural patients, the journey to a clinic or pharmacy can take hours and cost money that would otherwise buy food. Some delay refills until they can afford the trip, stretching the previous supply and running the risk of running out entirely. The result is a cycle where the most vulnerable patients face the highest barriers to consistent treatment.

Health economists argue that insulin should be treated as an essential medicine with reliable public funding, but the reality on the ground is more fragmented. Donor programs often focus on specific diseases or short-term goals, leaving chronic care underfunded. Without a stable budget line, clinics cannot guarantee supply, and patients bear the cost.

Practical Steps for Clinicians

Ask about insulin access at every screening visit. A simple question about whether the last prescription was filled, and how many doses were missed, turns the eye check into a fuller assessment of risk.

Document stockouts in the patient record. A note that the clinic had no insulin in March, and the patient rationed for three weeks, explains a retinal change that would otherwise look like poor adherence.

Link eye findings to a medication review. New retinopathy in a patient with stable glucose control should prompt a check on whether the insulin itself changed in supply, brand, or storage.

• Ask whether the last insulin prescription was filled and how many doses were missed.
• Record clinic stockouts and rationing periods in the patient's notes.
• Review medication supply whenever retinopathy appears or worsens.
• Counsel patients on the specific risks of splitting or skipping doses.
• Report recurring stockouts through district channels so they reach procurement.

Advocate for integrated supply planning at district level. Screening targets and insulin forecasts should be set together, because a retina camera without insulin is a diagnostic service that documents a preventable decline.

This article is informational and does not constitute personal medical advice. Patients should consult a qualified clinician about their own diabetes care and medication access.